, Volume 25, Issue 4, pp 255-256

Sipuleucel-T in Metastatic Castration-Resistant Prostate Cancer

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Prostate cancer is one of the most commonly diagnosed cancers among men in the US, second only to skin cancer,[1,2] with an estimated 217 730 new cases and 32 050 related deaths in 2010.[1] It accounts for ≈11% of cancer-related deaths among American men,[1] second only to lung cancer.[1,2] Currently, there are more than 2 million men in the US living with a diagnosis of prostate cancer,[1] the majority (almost two-thirds) being over the age of 65 years.[3]

Diagnosis of prostate cancer is usually made in men with localized disease, which is associated with a 5-year relative survival rate of 100% in the US.[4] Treatment at this stage may involve surgery, radiation therapy, or close monitoring.[57] For patients whose disease recurs after potentially curative surgical or radiation treatment, androgen-deprivation therapy is often used, but the disease eventually progresses in most patients.[8,9] Progression to distant disease involving distant lymph nodes or metastases to bone or other org

Adapted and reproduced from the original article published in Drugs 2011; 71 (1): 101–108